NIZ985X
Total Payments
$95,540
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $95,540 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $95,540 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I IB STUDY OF SUBCUTANEOUS RECOMBINANT HUMAN NIZ985 ALONE AND IN COMBINATION WITH PDR001 IN ADULTS WITH METASTATIC CANCERS | Novartis Pharmaceuticals Corporation | $95,540 | 0 |
Top Doctors Receiving Payments for NIZ985X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Madison, WI | $95,540 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $95,540
- Total Doctors 0
- Transactions 1
About NIZ985X
NIZ985X is a drug associated with $95,540 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $95,540 was paid across 1 transactions to 0 doctors.
The most common payment nature for NIZ985X is "Unspecified" ($95,540, 100.0% of total).
NIZ985X is associated with 1 research study, including "A PHASE I IB STUDY OF SUBCUTANEOUS RECOMBINANT HUMAN NIZ985 ALONE AND IN COMBINATION WITH PDR001 IN ADULTS WITH METASTATIC CANCERS" ($95,540).